AI Stock Analysis - Merck & Company (MRK)
Analysis generated January 9, 2026.
Merck Company, established in 1891, is a global leader in the healthcare sector, specializing in the innovation, research, and development of pharmaceuticals, vaccines, and animal health products. Emphasizing scientific excellence and breakthrough research, Merck aims to address prevalent health concerns worldwide, making significant contributions in the treatment of conditions such as cancer, diabetes, and infectious diseases.
Stock Alerts - Merck & Company (MRK)
 |
Merck & Company | January 22 Job postings are up by 30.3% in the last couple of days. |
|
Merck & Company | January 22 Reddit mentions are up by 750% in the last 24h. |
|
Merck & Company | January 17 Job postings are up by 28.5% in the last couple of days. |
|
Merck & Company | January 16 Julie Johnson (member of U.S. congress) is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Merck & Company
About Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
| Price | $107.92 |
| Target Price | Sign up |
| Volume | 7,880,000 |
| Market Cap | $270B |
| Year Range | $74.04 - $111.11 |
| Dividend Yield | 2.93% |
| PE Ratio | 14.31 |
| Analyst Rating | 59% buy |
| Earnings Date | February 3 '26 |
| Industry | Drug Manufacturers |
In the news
 |
Merck’s (MRK) Quality is Clear, but Growth Visibility Matters, TD Cowen NotesJanuary 26 - Yahoo |
|
Merck & Co., Inc. (MRK) and CEPI Launch Effort to Make Ebola Vaccine Cheaper and Easier to DistributeJanuary 24 - Yahoo |
|
Why Analysts See Merck (MRK) Differently After The Latest Price Target ResetJanuary 23 - Yahoo |
|
ABBV vs. MRK: An Oncology-Immunology Showdown for InvestorsJanuary 22 - Yahoo |
|
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year DataJanuary 22 - Yahoo |
|
Merck (MRK) Rises Higher Than Market: Key FactsJanuary 21 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 17.3B | 3.86B | 13.4B | 5.79B | 8.23B | 2.580 |
| Q2 '25 | 15.8B | 3.56B | 12.2B | 4.43B | 6.42B | 2.130 |
| Q1 '25 | 15.5B | 3.42B | 12.1B | 5.08B | 7.32B | 2.220 |
| Q4 '24 | 15.6B | 3.83B | 11.8B | 3.74B | 5.7B | 1.720 |
| Q3 '24 | 16.7B | 4.08B | 12.6B | 3.16B | 5.61B | 1.570 |
Insider Transactions View All
| Williams David Michael filed to sell 24,578 shares at $83.6. November 4 '25 |
| Smart Dalton E. III filed to sell 7,778 shares at $82.8. April 29 '25 |
| Oosthuizen Johannes Jacobus filed to sell 30,705 shares at $84.1. February 20 '25 |
| Williams David Michael filed to sell 24,123 shares at $85.3. February 13 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$224.44 1.3% | 44 |
 |
Eli Lilly and CompanyLLY |
$1039.51 2.2% | 62 |
 |
PfizerPFE |
$26.5 2.4% | 51 |
 |
AstrazenecaAZN |
$95.6 1.5% | 49 |
 |
AbbVieABBV |
$223.93 1.4% | 53 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Julie Johnson |
Jan 16, 26 | Sell | $1K - $15K |
| Gilbert Cisneros |
Jan 13, 26 | Buy | $1K - $15K |
| Julie Johnson |
Dec 12, 25 | Sell | $1K - $15K |
Read more about Merck & Company (MRK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Merck & Company
The Market Cap of Merck & Company is $270B.
As of today, Merck & Company's PE (Price to Earnings) ratio is 14.31.
Merck & Company will report its next earnings on February 3 '26.
Currently, the price of one share of Merck & Company stock is $107.92.
The MRK stock price chart above provides a comprehensive visual representation of Merck & Company's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Merck & Company shares. Our platform offers an up-to-date MRK stock price chart, along with technical data analysis and alternative data insights.
Yes, Merck & Company (MRK) offers dividends to its shareholders, with a dividend yield of 2.93%. This dividend yield represents Merck & Company's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Merck & Company in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Merck & Company are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
